Skip Navigation LinksHome > March 27, 2013 - Volume 27 - Issue 6 > Lower artemether, dihydroartemisinin and lumefantrine concen...
doi: 10.1097/QAD.0b013e32835cae3b
Clinical Science: Concise Communications

Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment

Lamorde, Mohammeda,b; Byakika-Kibwika, Paulinea,b,c; Mayito, Jonathana; Nabukeera, Lilliana; Ryan, Mairinb; Hanpithakpong, Waruneed; Lefèvre, Gilberte; Back, David J.f; Khoo, Saye H.f; Merry, Conceptaa,b,g

Collapse Box


Objective: To investigate the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine during rifampicin intake and after stopping rifampicin.

Study design: An open-label, two-phase, longitudinal drug interaction study with patients serving as their own controls.

Methods: We recruited HIV-1-seropositive Ugandan adults who were receiving rifampicin-based tuberculosis treatment and who did not have malaria. Pharmacokinetic sampling after six doses of artemether-lumefantrine was performed during rifampicin-based tuberculosis treatment (phase 1) and repeated at least 3 weeks after stopping rifampicin-based tuberculosis treatment (phase 2).

Results: Six and five patients completed phases 1 and 2, respectively. Median age and weight were 30 years and 64 kg. Artemether and dihydroartemisinin area under the concentration–time curve (AUC0–12h) were significantly lower by 89% [geometric mean ratio (GMR) 90% confidence interval (CI) 0.11, 0.05–0.26] and 85% (0.15, 0.10–0.23), respectively, during rifampicin-based treatment when compared to AUC0–12h after stopping rifampicin intake. Similarly, artemether and dihydroartemisinin Cmax were 83% (0.17, 0.08–0.39) and 78% (0.22, 0.15–0.33) lower, respectively, during rifampicin treatment. For artemether, mean (±SD) C12 was 0.5(±1.0) and 5.9(±2.5) ng/ml in phases 1 and 2, respectively. Corresponding values for dihydroartemisinin (DHA) were 0.3(±0.4) and 4.7(±2.0) ng/ml, respectively. Day 8 lumefantrine concentration was significantly lower by 84% (GMR 90% CI 0.16, 0.09–0.27), and AUCDay3-Day25 was significantly lower by 68% (GMR 90% CI 0.32, 0.21–0.49) during rifampicin-based treatment when compared to exposure values after stopping rifampicin.

Conclusion: Pharmacokinetic parameters for artemether-lumefantrine were markedly lower during rifampicin-based tuberculosis treatment. Artemether-lumefantrine should not be co-administered with rifampicin.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.